AI Verdict
KPTI has stronger fundamentals based on our AI analysis.
KPTI vs KOPN Fundamental Comparison
| Metric | KPTI | KOPN |
|---|---|---|
| Revenue | $146.1M | $890,171.0 |
| Net Income | $-196.0M | $-4.2M |
| Net Margin | -134.2% | -471.8% |
| ROE | N/A | -19.7% |
| ROA | -180.8% | -6.9% |
| Current Ratio | 1.12x | 1.47x |
| Debt/Equity | N/A | 0.00x |
| EPS | $-17.93 | $-0.03 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KPTI vs KOPN: Frequently Asked Questions
Is KPTI or KOPN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KPTI has stronger fundamentals. KPTI is rated STRONG SELL (95% confidence) while KOPN is rated STRONG SELL (85% confidence). This is not investment advice.
How does KPTI compare to KOPN fundamentally?
Karyopharm Therapeutics Inc. has ROE of N/A vs KOPIN CORP's -19.7%. Net margins are -134.2% vs -471.8% respectively.
Which stock pays higher dividends, KPTI or KOPN?
KPTI has a dividend yield of N/A or no dividend while KOPN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KPTI or KOPN for long term?
For long-term investing, consider that KPTI has STRONG SELL rating with 95% confidence, while KOPN has STRONG SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KPTI vs KOPN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KPTI vs KOPN, the AI consensus favors KPTI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.